Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
ALL MEDICAL CODES IN CATEGORY Oncology

2025 HCPCS code G9063

Oncology; disease status; limited to non-small cell lung cancer; extent of disease initially established as stage I (prior to neo-adjuvant therapy, if any) with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9078

Reports disease status of prostate cancer (limited to adenocarcinoma, T2 or T3a, Gleason 8-10, or PSA >20 at diagnosis) within a Medicare-approved demonstration project.

2025 HCPCS code G9096

Reports information on the disease status of a patient's esophageal cancer, specifically adenocarcinoma or squamous cell carcinoma, staged T1-T3, N0-N1 or NX, before neoadjuvant therapy, with no evidence of progression, recurrence, or metastasis (Medicare demonstration project).

2025 CPT code 0794T

This code represents the time spent by healthcare professionals submitting a patient's clinical and molecular data for algorithmic assessment to rank cancer treatment options based on biomarkers.

2025 HCPCS code G9105

Oncology; disease status; pancreatic cancer, limited to adenocarcinoma as predominant cell type; post r0 resection without evidence of disease progression, recurrence, or metastases.

2025 CPT code 0155U

PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) gene analysis for breast cancer, using formalin-fixed paraffin-embedded breast tumor tissue, to detect mutations, reported as PIK3CA gene mutation status.

2025 CPT code 0006M

mRNA expression profiling of 161 genes and alpha-fetoprotein levels in hepatocellular carcinoma tissue; algorithmic risk classification.

2025 CPT code 0422U

Analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, comparing it to a baseline test via next-generation sequencing; algorithm reports quantitative change from baseline.

2025 CPT code 0334U

Targeted genomic sequencing analysis of formalin-fixed paraffin-embedded (FFPE) solid tumor tissue DNA, examining 84 or more genes for variants, copy number changes, rearrangements, microsatellite instability, and tumor mutational burden.

2025 CPT code 0359U

Analysis of all prostate-specific antigen (PSA) structural isoforms using phase separation and immunoassay; plasma; algorithm reports cancer risk.

2025 CPT code 0113U

Measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum, following prostatic massage, using RNA amplification and fluorescence-based detection; algorithm reported as a risk score.

2025 CPT code 0362U

Gene expression profiling of 82 genes and 10 housekeeping genes via RNA sequencing from a fine needle aspirate or FFPE tissue specimen of papillary thyroid cancer, with algorithmic analysis classifying the molecular subtype and recurrence risk.

2025 CPT code 0421U

This code represents a fecal-based colorectal cancer screening test that analyzes the expression of eight genes and fecal hemoglobin, providing a positive or negative risk assessment for colorectal cancer.

2025 CPT code 0245U

Thyroid oncogene panel analysis using next-generation sequencing (NGS) to assess malignancy risk in indeterminate thyroid fine needle aspiration (FNA) specimens.

2025 CPT code 0019U

RNA gene expression analysis using whole transcriptome sequencing on formalin-fixed paraffin-embedded or fresh frozen tumor tissue; predictive algorithm reported as potential targets for therapeutic agents.

2025 CPT code 0211U

Next-generation sequencing (NGS) analysis of DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue; identifies variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapeutic associations.

2025 CPT code 0248U

Predicts brain or brain metastasis tumor response to twelve drugs using a 3D spheroid cell culture.

2025 CPT code 0356U

Evaluates cell-free DNA from oropharyngeal or anal specimens for 17 DNA biomarkers associated with HPV-related cancer; algorithmic analysis determines cancer recurrence likelihood.

2025 CPT code 0244U

Comprehensive genomic profiling of solid tumor tissue using next-generation sequencing (NGS) to analyze 257 genes for variations.

2025 CPT code 0083U

Oncology; response to chemotherapy drugs using motility contrast tomography of fresh or frozen tissue; reported as likelihood of sensitivity or resistance to drugs or drug combinations.

2025 CPT code 0315U

mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping) in formalin-fixed paraffin-embedded (FFPE) tissue from cutaneous squamous cell carcinoma (SCC), providing a categorical risk assessment (Class 1, 2A, 2B).

2025 CPT code 0342U

Multiplex immunoassay for pancreatic cancer markers in serum; diagnostic algorithm reported qualitatively.

2025 CPT code 0340U

Analysis of minimal residual disease (MRD) in plasma, personalized to each patient based on prior next-generation sequencing of tumor and germline DNA; reported as absence or presence of MRD, with disease-burden correlation if applicable.

2025 CPT code 0564T

This CPT code reports a drug-response assay evaluating the effectiveness of at least 14 chemotherapy drugs or combinations on cultured cancer stem cells and bulk tumor cells from a fresh tumor biopsy.

2025 CPT code 0391U

Next-generation sequencing (NGS) analysis of DNA and RNA from formalin-fixed paraffin-embedded (FFPE) solid tumor tissue, encompassing 437 genes, with an interpretive report for various genetic alterations and an algorithm-generated immunotherapy response score.

2025 CPT code 0317U

Four-probe fluorescence in situ hybridization (FISH) assay of whole blood to evaluate lung cancer risk in patients with indeterminate lung nodules.

2025 HCPCS code G9078

يُبلغ عن حالة مرض سرطان البروستاتا (يقتصر على السرطان الغدي أو T2 أو T3a أو Gleason 8-10 أو <a href="../medical-coding/reference/PSA" target="_blank" title="Medical Code PSA 2025">PSA</a> > 20 عند التشخيص) ضمن مشروع تجريبي معتمد من Medicare.

2025 HCPCS code G9135

Oncology; Disease status; Non-Hodgkin’s lymphoma, any cellular classification; Stage III, IV, not relapsed, not refractory.

2025 HCPCS code G9068

Oncology disease status limited to small cell and combined small cell/non-small cell; extent of disease initially established as limited with no evidence of disease progression, recurrence, or metastases (for use in a Medicare-approved demonstration project).

2025 HCPCS code G9125

Oncology disease status of chronic myelogenous leukemia (CML), limited to Philadelphia chromosome positive and/or BCR-ABL positive, blast phase not in hematologic, cytogenetic, or molecular remission. For use in a Medicare-approved demonstration project.

2025 HCPCS code G9113

Oncology; disease status; ovarian cancer, limited to epithelial cancer; pathologic stage IA-B (grade 1) without recurrence or progression.

2025 CPT code 0388U

Next-generation sequencing (NGS) analysis of 37 cancer-related genes in plasma for non-small cell lung cancer (NSCLC) patients, identifying single nucleotide variants, copy number variants, insertions/deletions, and structural variants, to aid in treatment decisions.

2025 CPT code 0428U

Oncology (breast), targeted hybrid-capture genomic sequence analysis panel, circulating tumor DNA (ctDNA) analysis of 56 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutation burden

2025 CPT code 0435U

Chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells. Categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations.

2025 CPT code 0048U

MSK-IMPACT™ (Integrated Mutation Profiling of Actionable Cancer Targets) test for solid organ neoplasia. Analyzes 468 cancer-associated genes for somatic mutations and microsatellite instability using targeted DNA sequencing.

2025 CPT code 0067U

Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score.

2025 CPT code 0047U

Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score.

2025 CPT code 0360U

Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy.

2025 CPT code 0090U

Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant).

2025 CPT code 0220U

Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score.

2025 CPT code 0111U

Targeted KRAS (codons 12, 13, and 61) and NRAS (codons 12, 13, and 61) gene analysis for colon cancer, using formalin-fixed paraffin-embedded tissue.

2025 CPT code 0250U

Targeted genomic sequence DNA analysis of 505 genes for somatic alterations, microsatellite instability, and tumor-mutation burden in solid organ neoplasms.

2025 CPT code 0376U

This test analyzes histologic features and clinical factors to determine the risk of distant metastases and prostate cancer-specific mortality. It may also include a predictive algorithm for androgen deprivation therapy response.

2025 CPT code 0375U

Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [i.e., transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score.

2025 CPT code 0363U

Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma.

2025 CPT code 0395U

Oncology (lung), multi-omics (microbial DNA by shotgun next-generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease.

2025 CPT code 0436U

Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy.

2025 CPT code 0433U

This code represents the EpiSwitch® Prostate Screening Test (PSE) from Oxford BioDynamics Inc., which analyzes five DNA biomarkers and prostate-specific antigen (PSA) levels to assess prostate cancer likelihood.

2025 CPT code 0387U

This CPT code represents the AMBLor® melanoma prognostic test by Avero® Diagnostics.It uses immunohistochemistry on FFPE melanoma tissue to identify two biomarkers and generate a risk score for disease progression.

2025 CPT code 0089U

Gene expression profiling for melanoma using RT-qPCR to analyze PRAME and LINC00518 genes from a superficial skin sample collected via adhesive patch.